Key result
Newer anticoagulants lack specific antidotes to completely reverse their effects, requiring alternative management strategies for anticoagulant-induced bleeding.
Why the study?
What is the bleeding risk and management strategy for bleeding complications in patients treated with newer anticoagulant agents?
What is the bleeding risk and management strategy for bleeding complications in patients treated with newer anticoagulant agents?
This review highlights the bleeding risks associated with newer anticoagulants and provides a management plan for bleeding complications given the lack of specific antidotes.
No takes yet. Share an insight, caveat, or question.
Requires alternative strategies for anticoagulant-related bleeding; leaves open need for targeted antidotes.
Crowther et al. (2008) conducted a review in Patients undergoing anticoagulant therapy. Newer anticoagulants vs. Heparin and coumarin was evaluated. Newer anticoagulants lack specific antidotes to completely reverse their effects, requiring alternative management strategies for anticoagulant-induced bleeding.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: